Munira Siddiqui, MD
Endocrinology, Diabetes & Metabolism · Safety Harbor, FLNPI 1033317250
Payments from drug & device makers
Across 478 payments — averaging $83.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$35K
- Dexcom, Inc.$849
- Tandem Diabetes Care, Inc.$838
- AbbVie$773
- Lilly USA, LLC$728
- Sanofi-aventis U.S. LLC$292
- plus $2K from 20 others
What the payments were for
- Consulting fees$2,9857%
- Speaking & faculty fees$29,51274%
- Food & beverage$7,54719%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 227 | $34,977 |
| Dexcom, Inc. | 34 | $849 |
| Tandem Diabetes Care, Inc. | 32 | $838 |
| AbbVie | 35 | $773 |
| Lilly USA, LLC | 52 | $728 |
| Sanofi-aventis U.S. LLC | 15 | $292 |
| Boehringer Ingelheim | 15 | $258 |
| AstraZeneca | 10 | $195 |
| Insulet Corporation | 7 | $175 |
| Amgen | 10 | $163 |
| Ascendis Pharma Endocrinology Inc | 4 | $107 |
| Abbott | 6 | $97 |
| Amneal Pharmaceuticals LLC | 5 | $80 |
| Recordati_rare_diseases_inc. | 2 | $67 |
| Bayer | 3 | $67 |
| Medtronic | 3 | $65 |
| Merck | 4 | $58 |
| Radius Health, Inc. | 2 | $53 |
| IBSA Pharma Inc. | 3 | $43 |
| BETA Bionics, Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Sequel Med Tech, LLC | 1 | $26 |
| Lifescan, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$17,508
- Ozempic$13,277
- Tresiba$945
- DEXCOM G7 GSS (161)$110
How this compares
$40,072 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 568 | $832,954 |
| TrulicityDulaglutide | 219 | $280,798 |
| JardianceEmpagliflozin | 230 | $260,035 |
| MounjaroTirzepatide | 209 | $233,077 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $133,501 |
| FarxigaDapagliflozin Propanediol | 114 | $118,352 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $115,822 |
| ProliaDenosumab | 57 | $98,869 |
| JanuviaSitagliptin Phosphate | 55 | $62,304 |
| Humalog Kwikpen U-100Insulin Lispro | 104 | $56,726 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $53,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $48,507 |
| Teriparatide | 11 | $33,875 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $30,265 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $25,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $34,977 | $846,457595 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $728 | $531,931477 claims |
| Boehringer IngelheimJardiance, Tradjenta | $258 | $282,329257 claims |
| AstraZenecaFarxiga | $195 | $118,352114 claims |
| AmgenProlia | $163 | $98,86957 claims |
| MerckJanuvia | $58 | $62,30455 claims |
| AbbVieSynthroid | $773 | $24,179220 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $80 | $6,448705 claims |
| Sanofi-aventis U.S. LLCLantus | $292 | $5,25011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Safety Harbor
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.